drugset / Trial / NCT02674763
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
Timeline
- Start
- 2016-03
- Primary completion
- 2019-06
- Completion
- 2019-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMGN779 | Unknown | — | Intravenous |